Nanogen To Host Conference Call on 2002 Fourth Quarter and Year-End Financial Results.Business Editors SAN DIEGO--(BUSINESS WIRE)--Jan. 30, 2003 Nanogen, Inc. (Nasdaq: NGEN NGEN Next Generation NGEN Next Generation Enterprise Network (US Navy Intranet Development Program) - news) will host a conference call on Thursday, February 6, 2003 at 4:30 p.m. EST to discuss 2002 fourth quarter and year-end financial results. The earnings release will be issued at close of market February 6. Nanogen management will host the conference call. Audio of the management's presentation will be available via live webcast on the investor relations Investor relations The process by which the corporation communicates with its investors. section of Nanogen's corporate website at www.nanogen.com, and will be archived until February 20. A digital recording of the call will also be available two hours after the completion of the conference call on February 6 until midnight on February 8, which may be accessed via telephone at (800) 642-1687 for US/Canada participants, and (706) 645-9291 for international participants. The conference ID, 7737301, will be required to listen to the playback. About Nanogen Nanogen is a leading provider of molecular diagnostics. The Company is seeking to establish the NanoChip(R) Molecular Biology molecular biology, scientific study of the molecular basis of life processes, including cellular respiration, excretion, and reproduction. The term molecular biology was coined in 1938 by Warren Weaver, then director of the natural sciences program at the Rockefeller Workstation as the standard platform for the detection of genetic mutations and to develop applications for future clinical use. To date, it has developed two ASRs for the detection of Factor V Leiden factor V Leiden Hematology A variant of factor V present in 3%-8% of Caucasians associated with a ↑ risk of DVT. See LETS, Hereditary thrombophilia. and the CFTR gene for cystic fibrosis cystic fibrosis (sĭs`tĭk fībrō`sĭs), inherited disorder of the exocrine glands (see gland), affecting children and young people; median survival is 25 years in females and 30 years in males. , and has internally validated five research protocols, four associated with cardiovascular disease Cardiovascular disease Disease that affects the heart and blood vessels. Mentioned in: Lipoproteins Test cardiovascular disease and one associated with hereditary hemochromatosis Hemochromatosis Definition Hemochromatosis is an inherited blood disorder that causes the body to retain excessive amounts of iron. This iron overload can lead to serious health consequences, most notably cirrhosis of the liver. , the most common form of iron overload Iron overload A side effect of frequent blood transfusions in which the body accumulates abnormally high levels of iron. Iron deposits can form in organs, particularly the heart, and cause life-threatening damage. disease. Nanogen markets its NanoChip(R) Molecular Biology Workstation to scientists and genomics laboratories. The NanoChip(R) System is intended for laboratory use only. For additional information please visit Nanogen's web site at www.nanogen.com. This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether patents owned or licensed by the Company will be developed into products, whether the Company's NanoChip(R) System can be successfully further commercialized, whether other products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, whether ASRs currently sold by the Company will become FDA-approved molecular diagnostic test kits, whether Nanogen will be successful in developing additional ASRs and protocols utilizing the NanoChip(R) System, whether current trends in product revenue will continue in the future, and other risks and uncertainties discussed under the caption "Factors That May Affect Results" and elsewhere in the Company's Form 10-K Form 10-K A report required by the SEC from exchange-listed companies that provides for annual disclosure of certain financial information. Form 10-K See 10-K. for the year ended December 31, 2001 filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. The Company disclaims any intent or obligation to update these forward-looking statements. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion